Compare
Zevra Therapeutics, Inc. vs Zymeworks Inc. vs Theravance Biopharma, Inc. vs UroGen Pharma Ltd.
| Latest fiscal year | Zevra Therapeutics, Inc. ZVRA | Zymeworks Inc. ZYME | Theravance Biopharma, Inc. TBPH | UroGen Pharma Ltd. URGN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $106.47M | $105.97M | $107.46M | $109.79M |
| Revenue growth (YoY) | +350.9% | +38.9% | +66.9% | +21.4% |
| Gross margin | n/a | n/a | n/a | 88.7% |
| Operating margin | -59.1% | -87.3% | -3.4% | -113.7% |
| Net margin | 78.2% | -76.6% | 98.5% | -139.8% |
| Net income | $83.23M | -$81.13M | $105.89M | -$153.49M |
| EPS (Diluted) | $1.35 | -$1.08 | $2.06 | n/a |
| Operating cash flow | -$1.60M | -$33.01M | $238.54M | -$162.44M |
| Free cash flow | -$2.43M | -$34.53M | $238.50M | -$162.73M |
| Cash & equivalents | $62.41M | $41.16M | $167.81M | $110.75M |
| Total assets | $284.73M | $346.53M | $485.57M | $200.46M |
| Total liabilities | $130.07M | $78.03M | n/a | $305.93M |
| Shareholders' equity | $154.66M | $268.50M | $296.72M | -$105.47M |
| Return on year-end equity | 53.8% | -30.2% | 35.7% | n/a |
| Shares outstanding | 56.85M | 74.64M | 51.07M | 48.35M |
Revenue, most recent five fiscal years
| Fiscal year | Zevra Therapeutics, Inc. | Zymeworks Inc. | Theravance Biopharma, Inc. | UroGen Pharma Ltd. |
|---|---|---|---|---|
| Latest | $106.47M Ended 2025-12-31 | $105.97M Ended 2025-12-31 | $107.46M Ended 2025-12-31 | $109.79M Ended 2025-12-31 |
| 1 year earlier | $23.61M Ended 2024-12-31 | $76.30M Ended 2024-12-31 | $64.38M Ended 2024-12-31 | $90.40M Ended 2024-12-31 |
| 2 years earlier | $27.46M Ended 2023-12-31 | $76.01M Ended 2023-12-31 | $57.42M Ended 2023-12-31 | $82.71M Ended 2023-12-31 |
| 3 years earlier | $10.16M Ended 2022-12-31 | $412.48M Ended 2022-12-31 | $51.35M Ended 2022-12-31 | $64.36M Ended 2022-12-31 |
| 4 years earlier | $28.65M Ended 2021-12-31 | $26.68M Ended 2021-12-31 | $55.31M Ended 2021-12-31 | $48.04M Ended 2021-12-31 |